<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1675378&amp;fmt=gif">

Biopharma M&A in 2027: Five Considerations for Successful Deal Execution

Biopharma dealmaking has regained momentum. But closing the deal is only half the battle. Delivering on its promise is where the real work begins.

After several years of uneven activity, life sciences M&A accelerated meaningfully in 2025 and into 2026. According to EY's 2026 Firepower report, life sciences M&A spending reached $240 billion in 2025, an 81% increase over 2024, even as deal volume declined. The momentum continued into 2026, with J.P. Morgan reporting $138.9 billion in biopharma M&A activity across 113 deals through the third quarter.

Large pharmaceutical companies continue to look externally to replenish pipelines ahead of major loss-of-exclusivity events, while buyers across the sector are pursuing differentiated science, later-stage assets, new modalities, and capabilities that can accelerate growth. At the same time, targeted tuck-in and bolt-on acquisitions remain an important part of the market, alongside asset acquisitions, divestitures, licensing transactions, and other increasingly tailored deal structures.

For many buyers, particularly emerging and mid-sized biopharmas, this creates both opportunity and a new execution challenge. Acquiring an asset or company may be episodic; successfully absorbing one is an organizational capability.

Heading into 2027, the question shifts from whether the deal has a compelling strategic rationale to whether the buyer and seller can translate that rationale into hundreds of interconnected decisions—about people, governance, clinical development, regulatory strategy, manufacturing, systems, contracts, data, and ways of working—without losing momentum on the underlying science.

As biopharma companies plan for 2027, five considerations can help improve the likelihood of success:

Maintain laser-focus on the deal thesis (your "why")

These big bets should tie directly to strategy, and the implementation of integration activities should focus on how we're setting ourselves up to accelerate strategy. Identify synergies early, and manage them alongside other key metrics for your business.

Integration planning starts early

Do not wait until deal-close appears imminent to figure out how integration will happen. Integration management offices / teams should be stood up well before diligence is completed, and should have clear objectives and timelines for delivery (aligned to synergies - not just to contractual obligations).

Integration (and transition) is a joint activity

Amid divestitures and out-licensing, big pharmas tend to be urgently working to shift resources away from these deprioritized programs, which can create risks to integration success. Determine well before deal-close, through diligence and integration planning, what is needed from your partners, and build joint plans, commitments, and incentives to ensure collaborative execution.

Alignment is never "overkill"

Integration tends to be highly cross-functional and interdependent. Be wary of assuming that everyone knows the strategy, and therefore is ready to execute in an aligned way. If we're already aligned, agreeing on documented roles and responsibilities should be easy (and if its not easy, we're not that aligned!). Slow is smooth, smooth is fast.

People come first

Integration is disruptive. When we begin working with a new leadership team on an integration effort, we often joke that we're the only ones who actually want this additional work. Early and ongoing engagement with your people is essential to maintaining employee experience, productivity, and retention through integration periods.

Vantage Partners' Integration Management team is focused on helping our clients align and advance through interesting times in the biopharma space. We are always open to a conversation, so please let us know if we can help.

Visit our Integration Management page to learn more.